Immune checkpoint inhibitor response
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
... a response rate of ...cause immune-related adverse events (irAE). Higher response rates have been reported when ICIs are combined, but this coincides with an increase and different kinetics of irAEs ...
11
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
... in immune-based response in high mutation load MMR-deficient tumors and moder- ate overall survival than in MMS-stable ...target. Immune editing, clonal T cells repertoire deletions, and strong ...
5
Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis
... the immune system via several mechanisms, including cell signaling, interactions with antigen-presenting cells, and both T- and B-cell medi- ated immunity ...
11
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis
... with ground glass and consolidative components (Figure 1), and the exclusion of infectious etiologies (with sputum cultures or bronchoalveolar lavage [BAL]). There are currently no diagnostic biomarkers for CIP, so the ...
12
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
... treatment response, she was treated with ...with checkpoint inhibitor therapy, <1% experienced thrombocytopenia following immune checkpoint inhibition, and of these, most had ...
6
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
... first immune checkpoint inhibitor (ICI) to be approved by the US Food and Drug Administration for use in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) progressing on or ...
13
Immune Checkpoint Inhibitor Related Neuropathic Adverse Effects on Cancer Patients
... or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response sys- tem by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, ...
12
A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report
... antitumor immune responses within the tumor microenvironment, but it re- mains largely speculative whether the intrinsic microen- vironmental characteristics associated with the histologic phenotype or HPV status ...
6
Search Terms: adverse events, immune checkpoint inhibitor, myasthenia gravis
... Diagnosing myasthenia gravis is often straightforward as symptoms are quite characteristic, including fluctuation of ocular or bulbar symptoms and/or weakness of neck and proximal limb muscles without sensory deficits ...
41
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
... partial response in a pa- tient with metastatic BCC treated with a PD-1 inhibitor (REGN2810), as well as an ongoing complete response in a patient with metastatic ...cellular immune system ...
5
Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report
... Immune checkpoint inhibitors can be used in the treat- ment of melanoma, non-small cell lung cancer, Hodgkin lymphoma, and small cell lung ...promotes immune activation and anti-tumor ...
6
Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
... an immune checkpoint ...Neurologic immune-related adverse events may be serious and potentially life-threatening complications requiring immediate immunosuppressive ...of immune-related ...
8
Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
... of the pancreas (such as peripancreatic fat stranding, pan- creatic enlargement with heterogeneous enhancement, and segmental hypoenhancement). We defined ICIPI as elevation of lipase with and without clinical ...
12
Imaging of tumour response to immunotherapy
... non-specific immune-stimulants such as cytokines, cancer vaccines, immune checkpoint inhibitors (ICIs), and adoptive T cell ...treatment response in some ...with immune and T cell ...
15
Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer
... In response to the immunosuppressive microenvironment of liver cancer, immunological checkpoint inhibitors reactivate the patient’s own immune activity, destroy the immunosuppressive ...
8
Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma
... of immune-related ...neurological immune-related adverse events (irAE) have been de- scribed ...to immune check- point inhibitors (ICI) is estimated to occur in up to ...
6
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
... of immune-related organ pathology in patients treated with immune checkpoint ...tumor response with regression of skin and lung metastases and fatal progression of metastatic disease in the ...
8
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management
... Some cases showed an increase in intraepithelial lympho- cytes and/or apoptosis, but these features were inconsis- tent. Histopathological features neither correlate with the different types of immune ...
8
<p>Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential</p>
... Improving patient selection for immuno-oncology trials and real-life setting is an active area of research to better iden- tify, in particular, fast progressors. Massard et al developed a tool (FastProgIO) predicting ...
8
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
... Owing to the immunological mechanism of ICPIs, their adverse effects collectively fall under the umbrella of immune-related adverse events (irAEs). Although ICPI-induced irAEs can affect virtually any organ ...
11